Multiple sclerosis-secondary progressive multi-arm randomisation trial (MS-SMART): a multiarm phase IIbrandomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
Lastly, it is important to remark that ED could represent an early predictor of CV events and the diagnosis of vasculogenic ED at PDU, and particularly at dynamic PDU as the gold standard diagnostic tool, both in patients with or without additional CV risk factors and/or comorbidities, can help to recognize eventual arterial diseases in biggest distal vessels [35, 39,40,41]
The patient remains on daily zinc L-carnosine therapy
An individual may establish an HSA if he or she is covered by a qualified health plan a plan with a high deductible (at least $1,600 for single coverage and $3,200 for family coverage in 2025 or $1,500 and $3,000, respectively, in 2024) that also meets other requirements
doi: 10.1038/s41598-019-43320-5
